Return to Article Details
EXTENDED DUAL ANTIPLATELET THERAPY UTILIZING P2Y12 INHIBITORS FOLLOWING ACS/PCI : AN EVALUATION OF ISCHEMIC ADVANTAGES VERSUS HEMORRHAGIC RISKS
Download
Download PDF